A Phase 1b/2, Multicenter, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), in Combination with Atezolizumab with or without Carboplatin as First-line Induction or Maintenance, in Subjects with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

The purpose of this study is to learn more about an investigational drug called Ifinatamab Deruxtecan or I-DXd. An investigational drug is a drug that is not approved for your disease. It is being studied to see if it is safe and if your disease or medical condition improves while taking it. I-DXd is a type of drug called an antibody drug conjugate, which is made up of 2 parts: an antibody and an anticancer drug. The antibody part binds to a protein commonly found on tumor cells called humanized anti B7 homologue 3 (B7-H3), while the drug is released to attack cancer cells. By using an antibody, the drug should reach the tumor directly while sparing healthy cells. This should decrease the side effects caused by chemotherapy and make sure that tumor cells are effectively killed